



**Canadian Journal of
Cardiology**

**Journal canadien
de cardiologie**

www.onlinecjc.ca

*Journal of the
Journal de la*



Canadian
Cardiovascular
Society

Société
canadienne
de cardiologie

For Issue Highlights with article summaries, go to www.onlinecjc.ca.

Viewpoint

S1 β -Adrenergic Receptor Blockers in Hypertension

Sheldon W. Tobe, MD, MScCH (HPTE), FRCPC, FACP, FASH

Review

S3 β -Adrenoceptors as Molecular Targets in the Treatment of Hypertension

Stephen S.G. Ferguson, PhD, and Ross D. Feldman, MD

S9 Contemporary Use of β -Blockers: Clinical Relevance of Subclassification

Luc Poirier, BPharm, MSc, and Sheldon W. Tobe, MD, MScCH (HPTE), FRCPC, FACP, FASH

S16 β -Blockers in Hypertension: Studies and Meta-analyses Over the Years

Pierre Larochelle, MD, PhD, Sheldon W. Tobe, MD, MScCH (HPTE), FRCPC, FACP, FASH, and Yves Lacourcière, MD

S23 Central Blood Pressure as an Index of Antihypertensive Control: Determinants and Potential Value

Luc Trudeau, MD, FRCPC

S29 Nebivolol: Vasodilator Properties and Evidence for Relevance in Treatment of Cardiovascular Disease

Jonathan G. Howlett, MD, FRCPC, FACC

S38 β -Blockers and Atrial Fibrillation: Hypertension and Other Medical Conditions Influencing Their Use

Paul Dorian, MD, and Paul Angaran, MD

S42 Combining Other Antihypertensive Drugs With β -Blockers in Hypertension: A Focus on Safety and Tolerability

Tiffany R. Richards, BSc, and Sheldon W. Tobe, MD, MScCH (HPTE), FRCPC, FACP, FASH

Systematic Review/Meta-analysis

S47 Atenolol vs Nonatenolol β -Blockers for the Treatment of Hypertension: A Meta-analysis

Laura M. Kuyper, MD, and Nadia A. Khan, MD, MSc

Departments

A6 Information for Readers

Publication Mail Agreement 41536048
Return undeliverable Canadian addresses to:
Trans continental Printing, 737 Moray St,
Winnipeg, MB R3J 3S9

Printed in Canada

On the Cover: Schematic showing contemporary ideas about the receptor response to β -adrenergic agonists vs different kinds of antagonists (β -blockers): partial agonists, neutral antagonists, and inverse agonists. From the article, β -Adrenoceptors as a Molecular Targets in the Treatment of Hypertension, by Ferguson and Feldman, pages S3-S8 of this issue.